This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

WCLC, Barcelona, Spain 7-10 September 2019

A Phase IIIb open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: Final analysis

Yi-Long Wu, Haiyan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, BJ Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Kaimin Pang, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou

wclc_2019_poster_wu_1200.66_final_analysis.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this

A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis

Wu Y-L, et al. WCLC 2017. P3.01-036

FOR HEALTHCARE PROFESSIONALS ONLY

image